Description du projet
Traitement respiratoire numérique et coach d’inhalation
La BPCO et l’asthme sont des maladies pulmonaires graves, potentiellement mortelles, et prédisposées à des aggravations. Ce sont les maladies respiratoires chroniques (MCR) les plus courantes. Bien qu’elles ne soient pas guérissables, leur traitement reste possible en administrant des médicaments dans les poumons à l’aide d’inhalateurs. Malheureusement, 90 % des patients utilisent leur inhalateur de manière incorrecte, ce qui se traduit par une médication insuffisante et un traitement dont les résultats ne sont pas optimaux. L’application KATA, financée par l’UE, est un assistant numérique personnalisé, piloté par l’IA, qui aide les patients souffrant de maladies respiratoires à inhaler leurs médicaments de manière plus efficace. L’application pour smartphone Kata montre comment procéder à une bonne inhalation en fournissant des conseils et un retour d’information en temps réel. Associée à des dossiers médicaux, à un programme d’exercices et à un contenu éducatif, cette application vise à devenir un coach personnel complet en matière de maladies respiratoires.
Objectif
IIncreasing industrialization in emerging countries, high levels of pollution and smoking is leading to a rise in chronic respiratory diseases (CRDs) worldwide. Even though CRDs are not curable, there are efficient treatments against them, mainly delivering medication into the lungs using inhalers. Unfortunately, 90% of the patients are not using correctly their inhalers, leading to chronic under-use of the prescribed medication and poor management of the disease. VisionHealth, founded in 2017, provides CRD patients with a unique therapy companion to efficiently manage CRDs – the Kata app. With Kata, dynamic training and personalized feedback for optimal use of any commercial inhaler is, for the first time, possible using a combination of advance technology: (1) Machine Vision (MV) using a SIFT algorithm to discern among inhalers and handling, (2) Voice Recognition (VR) recognizing the drug intake and predicting it with RNN architecture, (3) Machine Learning (ML) linking MV and VR inputs and creating models to predict users’patterns, and (4) Augmented Reality (AR) guiding the user in real time based on the ML input. Kata will empower its users to master the usage of their inhaler by Kata’s personalized digital assistance. Kata will ensure high medication compliance in each inhalation to improve patient’s quality of life and functional capacities. Customers of Kata, healthcare insurance companies (HiCs) and pharmaceutical companies, will be able to reduce costs associated with poor patient health outcome and low adherence to medication. Moreover, these companies will be able to redefine their policies moving towards a patient-centered healthcare using the data collected from Kata’s users. VisionHealth aims at stablishing their business strategies and technical roadmap to launch an advance app into the market that will improve CRD patient’s health and, in addition, will provide highly valuable data to optimize HiCs’ and pharmaceutical companies’ activities.
Champ scientifique
- medical and health sciencesclinical medicinepneumologyasthma
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- natural sciencescomputer and information sciencesartificial intelligencecomputer vision
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
80339 MUNCHEN
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.